Adjunctive treatment with infliximab in pediatric immunoglobulin A (IgA) vasculitis: A case report

Barbara Castelli; Edoardo Marrani; Eleonora Fusco; Caporalini Chiara; Ilaria Pagnini; Gabriele Simonini

doi:10.1111/pde.15077

Adjunctive treatment with infliximab in pediatric immunoglobulin A (IgA) vasculitis: A case report

Pediatr Dermatol. 2022 Nov;39(6):946-949. doi: 10.1111/pde.15077. Epub 2022 Jul 2.

Authors

Barbara Castelli¹, Edoardo Marrani¹, Eleonora Fusco¹, Caporalini Chiara², Ilaria Pagnini¹, Gabriele Simonini^{1

3}

Affiliations

¹ Rheumatology Unit, AOU Meyer Children's Hospital, Florence, Italy.
² Division of Pathological Anatomy, AOU Meyer Children's Hospital, University of Florence, Florence, Italy.
³ NEUROFARBA Department, University of Florence, Florence, Italy.

PMID: 35778929
DOI: 10.1111/pde.15077

Abstract

Immunoglobulin A vasculitis (IgAV) is the most common childhood vasculitis affecting small vessels. No clear recommendations are available for severe pediatric cases, and until now, anti-TNF agents have had a limited role in IgAV management. In this report, we describe a pediatric case of severe IgAV, successfully treated with combined therapy including the anti-TNF, infliximab.

Keywords: Henoch-Schönlein purpura; IgA vasculitis; infliximab; monoclonal antibodies; vasculitis.

Publication types

Case Reports

MeSH terms

Child
Humans
IgA Vasculitis* / drug therapy
Infliximab* / therapeutic use
Tumor Necrosis Factor Inhibitors* / therapeutic use

Substances

Infliximab
Tumor Necrosis Factor Inhibitors